Cite

HARVARD Citation

    Whyte, M. et al. (2019). Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet. 7 (3), pp. 189-199. [Online]. 
  
Back to record